Skip to main content
SpringerLink
Log in

Treatment of Early Unfavorable Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1068 Accesses

Abstract

Early unfavorable or intermediate-stage Hodgkin lymphoma usually includes patients in stages I and IIA with clinical risk factors such as large mediastinal mass, extranodal disease, high ESR, or more than three or four nodal areas involved. In addition, selected stage IIB patients are also included in this risk group. The treatment for these patients is based on four cycles of ABVD chemotherapy followed by involved-field radiotherapy or a more aggressive approach with two cycles of BEACOPP escalated followed by two cycles of ABVD. More recently, the use of PET to guide treatment intensity or the use of additional radiotherapy in PET-negative patients has been advocated. New drugs such as brentuximab vedotin or checkpoint inhibitors have been incorporated into clinical trials. This chapter will give you an overview on the recent and current treatment approaches and will highlight the discussion on PET-guided treatment and new drugs in this setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7(11):1630–1636

    Article  CAS  Google Scholar 

  2. Kostakoglu L, Cheson BD (2014) Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging 41(5):1004–1027

    Article  Google Scholar 

  3. Stevens WB, van Krieken JH, Mus RD et al (2012) Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. Ann Oncol 23(10):2676–2681

    Article  CAS  Google Scholar 

  4. Eichenauer DA, Aleman BMP, Andre M et al (2018) Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv19–iv29

    Article  CAS  Google Scholar 

  5. El-Galaly TC, d’Amore F, Mylam KJ et al (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30(36):4508–4514

    Article  Google Scholar 

  6. Klimm B, Goergen H, Fuchs M et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol 24(12):3070–3076

    Article  CAS  Google Scholar 

  7. Specht L, Nordentoft AM, Cold S, Clausen NT, Nissen NI (1988) Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 61(8):1719–1727

    Article  CAS  Google Scholar 

  8. Gobbi PG, Ghirardelli ML, Solcia M et al (2001) Image-aided estimate of tumor burden in Hodgkin’s disease: evidence of its primary prognostic importance. J Clin Oncol 19(5):1388–1394

    Article  CAS  Google Scholar 

  9. Cottereau AS, Versari A, Loft A et al (2018) Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131(13):1456–1463

    Article  CAS  Google Scholar 

  10. Spina V, Bruscaggin A, Cuccaro A et al (2018) Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 131(22):2413–2425

    Article  CAS  Google Scholar 

  11. Schaapveld M, Aleman BM, van Eggermond AM et al (2015) Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 373(26):2499–2511

    Article  CAS  Google Scholar 

  12. Baxstrom K, Peterson BA, Lee C, Vogel RI, Blaes AH (2018) A pilot investigation on impact of participation in a long-term follow-up clinic (LTFU) on breast cancer and cardiovascular screening among women who received chest radiation for Hodgkin lymphoma. Support Care Cancer 26(7):2361–2368

    Article  CAS  Google Scholar 

  13. Cutter DJ, Schaapveld M, Darby SC et al (2015) Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 107(4):djv008

    Article  Google Scholar 

  14. Hahn E, Jiang H, Ng A et al (2017) Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol Phys 98(5):1116–1123

    Article  Google Scholar 

  15. Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21(19):3601–3608

    Article  Google Scholar 

  16. Ferme C, Eghbali H, Meerwaldt JH et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357(19):1916–1927

    Article  CAS  Google Scholar 

  17. Sasse S, Brockelmann PJ, Goergen H et al (2017) Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol 35(18):1999–2007

    Article  CAS  Google Scholar 

  18. Eich HT, Diehl V, Gorgen H et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28(27):4199–4206

    Article  Google Scholar 

  19. Ferme C, Thomas J, Brice P et al (2017) ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d’Etude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. Eur J Cancer 81:45–55

    Article  Google Scholar 

  20. von Tresckow B, Plutschow A, Fuchs M et al (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30(9):907–913

    Article  Google Scholar 

  21. Meyer RM, Gospodarowicz MK, Connors JM et al (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366(5):399–408

    Article  CAS  Google Scholar 

  22. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746–3752

    Article  CAS  Google Scholar 

  23. Simontacchi G, Filippi AR, Ciammella P et al (2015) Interim PET after two ABVD cycles in early-stage Hodgkin lymphoma: outcomes following the continuation of chemotherapy plus radiotherapy. Int J Radiat Oncol Biol Phys 92(5):1077–1083

    Article  Google Scholar 

  24. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068

    Article  Google Scholar 

  25. Barrington SF, Kirkwood AA, Franceschetto A et al (2016) PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study. Blood 127(12):1531–1538

    Article  CAS  Google Scholar 

  26. Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607

    Article  CAS  Google Scholar 

  27. Andre MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in Stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(16):1786–1794

    Article  CAS  Google Scholar 

  28. Straus DJ, Jung SH, Pitcher B et al (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132(10):1013–1021

    Article  CAS  Google Scholar 

  29. Hoppe RT, Advani RH, Ai WZ et al (2017) Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(5):608–638

    Article  Google Scholar 

  30. Younes A, Connors JM, Park SI et al (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348–1356

    Article  CAS  Google Scholar 

  31. Fornecker L, Lazarovici J, Aurer I et al (2017) PET-based response after 2 cycles of Brentuximab Vedotin in combination with AVD for first-line treatment of unfavorable early-stage Hodgkin lymphoma: first analysis of the primary endpoint of breach, a randomized phase II Trial of Lysa-FIL-EORTC intergroup. Blood 130(Suppl 1):736

    Google Scholar 

  32. Kumar A, Casulo C, Advani RH et al (2017) A Pilot Study of Brentuximab Vedotin and AVD chemotherapy followed By 20 Gy involved-site radiotherapy in early stage, Unfavorable Risk Hodgkin Lymphoma. Blood 130(Suppl. 1):734

    Google Scholar 

  33. Ramchandren R, Fanale MA, Rueda A et al (2017) Nivolumab for newly diagnosed advanced-stage Classical Hodgkin Lymphoma (cHL): results from the phase 2 checkmate 205 study. Blood 130(Suppl 1):651

    Google Scholar 

  34. UK RAPID study: NCT 00003849.

    Google Scholar 

  35. Chen R, Zinzani PL, Fanale MA et al (2017) Phase II study of the efficacy and safety of Pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125–2132

    Article  CAS  Google Scholar 

  36. Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189

    Article  CAS  Google Scholar 

  37. Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283–1294

    Article  CAS  Google Scholar 

  38. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Université Catholique de Louvain, CHU UcL Namur, Yvoir, Belgium

    Marc P. E. André

  2. Department of Internal Medicine I, German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany

    Andreas Engert

Authors
  1. Marc P. E. André
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc P. E. André .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University Hospital Cologne, Köln, Nordrhein-Westfalen, Germany

    Andreas Engert

  2. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

André, M.P.E., Engert, A. (2020). Treatment of Early Unfavorable Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-32482-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32482-7_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32481-0

  • Online ISBN: 978-3-030-32482-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation